These opportunities may take the form of new Concept Clearances and RFPs that specifically stimulate research areas for human diversity using exclusively human-based methods.ĬHANGE THE REVIEW PROCESS: Overhaul the scientific review process so that (a) human-based research and (b) diversity are major factors in the scientific criteria and numerical "impact scores". These new projects must explicitly address human diversity factors. Shift this funding towards human-based methods of human diversity.ĬREATE NEW FUNDING: Create new dedicated human-based neuroscience research funding and other resources for high-quality basic neuroscience and preclinical ADRD research. REPORTING & REPRIORITIZATION: Report the number of animal model grants. Our six specific calls to action include: This should start by the creation of a new action plan for diversity factors in preclinical research. Research of diversity factors in ADRD must be clearly indivisible from research of the mechanisms and phenomenology of the disease. We urge the national leadership to rebuild the framework of scientific practice. We cannot and should not reduce highly complex risk factors and human diversity factors into narrow subsets of features in animal models.įortunately, there are multitudes of modern ways to study the impact of human diversity on ADRD throughout many scales of biological and environmental interaction. To be clear: Understanding human diversity will require human-based approaches. Without these human-based approaches that factor in diversity we hold back our understanding of ADRD and we prevent potential therapies from being developed and effectively applied in a highly heterogeneous society. Thanks to substantial commitments from the public, the NIH has resources to immediately carve out new priorities to address these gaps in ADRD preclinical research. Integration of diversity must be foundational and start with human-based research in the therapeutic discovery phase within "disease mechanism and translational tools". Relegation of the study of these factors to "the population studies and precision medicine" implementation areas or cross-cutting themes of the National Plan are insufficient. We call on the Advisory Council to recommend immediate action by the National Institutes of Health (NIH) to integrate diversity and health disparities factors throughout the entirety of the therapeutic development process. Roadmaps and research implementation areas were being developed, but in practice the National Plan largely conceptualizes these issues as being addressed in clinical trials and care services. The cracks in our ADRD systems of care have now become fissures.Īlthough the Advisory Council had already recognized that diversity and health disparities were major issues prior to COVID-19, fundamental issues were not addressed. Disparities in care and in research have clearly widened due to the global pandemic. Although it has been encouraging to see the presentations on how we may address emergency preparedness and advance health equity, these are not sufficient. The COVID-19 pandemic has exposed issues that we as the Alzheimer's Disease and Related Dementias (ADRD) community have known for some time. We are a non-profit health advocacy group based in Washington D.C. I am the Medical Research Program Director for the Physicians Committee for Responsible Medicine. PLEASE NOTE: The Public Comments included on this page are not an endorsement of the views or information by National Alzheimer's Project Act, its Advisory Council members, the Administration, or the federal agencies and organizations involved.Ĭomments and questions, or alerts to broken links, should be sent to contact us if you would like a topic added here.Ģ020 Comments JULY 2020 COMMENTS A. Public Comments made at Advisory Council meetings are included here, but can also be found with meeting material available at. Information can be found by chosing typing a keyword, phrase or name in the "Search for." box above (under the date this page was last updated). Slight editing may be necessary when included, but email context will not be changed. Emails considered threatening or offensive, or found to be spam, will not be included on this page. Emails can be sent to and will be included on this page. Comments can be about Advisory Council meetings, NAPA and its documents, or issues involving Alzheimer's disease and related dementias. The Advisory Council on Alzheimer's Research, Care, and Services, as well as the agencies/organizations that are in the National Alzheimer's Project Act, invite anyone to submit comments.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |